Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02340208 | A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 | completed | Phase 1 / Phase 2 | 76 | Helix BioPharma CorporationINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02751385 | Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 | 2 | Boehringer IngelheimINDUSTRY | 1 | Mar 14, 2019 |
| NCT03871205 | Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | unknown | Phase 1 | 30 | Shenzhen People's HospitalOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00153842 | A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer | terminated | Phase 1 / Phase 2 | 33 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT02846792 | Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 5 | University of WashingtonOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT02040870 | LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | completed | Phase 1 / Phase 2 | 103 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02346370 | A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC(PRIMAL) | terminated | Phase 1 | 16 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01999738 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | completed | Phase 1 | 93 | EndocyteINDUSTRY | 1 | Feb 7, 2019 | clinicaltrials |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | terminated | Phase 1 | 29 | Eli Lilly and CompanyINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT02258607 | Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase | terminated | Phase 1 | 21 | Sierra Oncology LLC - a GSK companyINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03053219 | Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment | completed | Phase 1 | 7 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | unknown | Phase 1 | 85 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT02364362 | A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 18, 2019 | clinicaltrials |
| NCT03556436 | Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 | completed | Phase 1 | 24 | Yuhan CorporationINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01891669 | A Study Of PF-06263507 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 26 | PfizerINDUSTRY | 1 | Jan 9, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02860780 | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 14, 2018 | clinicaltrials |
| NCT01323062 | Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects | completed | Phase 1 | 26 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT02655913 | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer(VCONSCLC) | completed | Phase 1 / Phase 2 | 97 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Nov 30, 2018 | clinicaltrials |
| NCT02457793 | A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 24 | Genentech, Inc.INDUSTRY | 1 | Nov 20, 2018 | clinicaltrials |
| NCT00745732 | Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 14, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT00735878 | Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer | terminated | Phase 1 / Phase 2 | 20 | Konstantin DragnevOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT02580708 | Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 7 | Clovis Oncology, Inc.INDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT00352950 | Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | AmgenINDUSTRY | 0 | Sep 6, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02450656 | Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer(M14AFS) | unknown | Phase 1 / Phase 2 | 320 | The Netherlands Cancer InstituteOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT01871805 | A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 134 | Hoffmann-La RocheINDUSTRY | 2 | Aug 21, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT01457469 | Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer | completed | Phase 1 | 6 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03370159 | CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT02317016 | Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 4 | Jul 31, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT02025114 | Selumetinib in Combination With Gefitinib in NSCLC Patients | completed | Phase 1 / Phase 2 | 34 | National Taiwan University HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT02835833 | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | completed | Phase 1 | 21 | University of Alabama at BirminghamOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT00923741 | Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer | completed | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01234038 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel(NSCLC) | completed | Phase 1 / Phase 2 | 116 | Ionis Pharmaceuticals, Inc.INDUSTRY | 4 | Jun 27, 2018 | clinicaltrials |
| NCT01159964 | Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery | terminated | Phase 1 | 60 | GlaxoSmithKlineINDUSTRY | 6 | Jun 18, 2018 | clinicaltrials |
| NCT02956551 | Personalized DC Vaccine for Lung Cancer(SKLB1608) | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 31, 2018 | clinicaltrials |
| NCT02252796 | Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer(HySBst) | terminated | Phase 1 | 1 | West Virginia UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT03527251 | Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC(SEQUENCE) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01607554 | Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 2 | New Mexico Cancer Research AllianceOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT01139775 | A Study in Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 76 | Eli Lilly and CompanyINDUSTRY | 2 | May 18, 2018 | clinicaltrials |
| NCT01204099 | Study of PX-866 and Docetaxel in Solid Tumors | completed | Phase 1 / Phase 2 | 223 | Cascadian Therapeutics Inc.INDUSTRY | 2 | May 16, 2018 | clinicaltrials |
| NCT03525782 | Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC | unknown | Phase 1 / Phase 2 | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT03515252 | Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer | completed | Phase 1 | 20 | Ivy Life Sciences, Co., LtdINDUSTRY | 0 | May 9, 2018 | clinicaltrials |
| NCT00078390 | Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | ShionogiINDUSTRY | 1 | May 2, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Mar 14, 2019source: clinicaltrials